Ironwood Pharmaceuticals

IRWD

Market cap $535M

Ironwood Pharmaceuticals is downgraded from a 'Buy' to a 'Sell' due to pipeline setbacks and declining LINZESS sales. IRWD declined to exercise its option on CNP-104 for PBC after disappointing data, removing a key pipeline catalyst. LINZESS U.S. sales dropped 6% to $864.5M in 2025, casting doubt on management's bullish 2026 sales guidance of $1.125–$1.175B.

Ironwood swings to Q4 loss as revenues plunge 47% year over year, missing estimates and sending shares down.

Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2025 Earnings Call Transcript

Ironwood Pharmaceuticals (IRWD) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.02 per share a year ago.

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full‑year 2025 results and recent business performance. “In 2025, LINZESS delivered 11% EUTRx demand growth year-over-year, continuing to strengthen its position as the prescription market leader for the treatment of IBS-C and CIC, surpassing 5.7.

IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.

IRWD has the edge over BHC with high Linzess demand and upbeat 2026 revenue outlook offsetting pipeline and pricing risks.

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its fourth quarter and full year 2025 investor update conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 25, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 8188306. To access the webcast, please visit the Investors & Media section o.

Ironwood surges 307% in six months on rising Linzess demand and an upbeat 2026 revenue outlook. The company is also making good pipeline progress.

Contrary to what investors have seen this earnings season, earnings growth is traditionally one of the key indicators of stock price growth. For calendar year 2026, FactSet forecasts earnings growth of companies in the S&P 500 to come in at 15%.